Advertisement
GlaxoSmithKline
Subscribe to GlaxoSmithKline

The Lead

Deal Flurry Shows Drug Makers’ Move to Specialization

April 24, 2014 8:58 am | Videos | Comments

The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.            

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling,...

Novartis and Glaxo Deal Reshapes Pharma Industry

April 22, 2014 8:58 am | Videos | Comments

Novartis completed about $25 billion of transactions in its product portfolios, including the...

Novartis, GSK, Lilly in Multibillion-Dollar Deals

April 22, 2014 4:28 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday...

View Sample

FREE Email Newsletter

FDA Approves Arzerra for Chronic Lymphocytic Leukemia

April 18, 2014 8:05 am | News | Comments

GlaxoSmithKline and Genmab A/S announced that the FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate.

GlaxoSmithKline Discloses New Bribery Inquiries

April 16, 2014 12:40 pm | by The Associated Press | News | Comments

British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company said Wednesday that it started looking into the conduct of "a small number of individuals" in December. It says the investigation is ongoing.

FDA Approves Injectable Diabetes Drug from Glaxo

April 15, 2014 5:32 pm | by The Associated Press | News | Comments

The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The agency cleared the company's drug, Tanzeum, to help patients control their blood sugar levels, in combination with diet and exercise.  

Advertisement

Report: Glaxo Bribed Doctors in Poland

April 14, 2014 9:25 am | News | Comments

The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. A "Panorama" show to air Monday evening quotes a former sales representative for the company saying doctors there were paid to prescribe its drugs.

GSK Recalls Weight Loss Drug

March 28, 2014 9:11 am | by The Associated Press | News | Comments

GlaxoSmithKline is recalling the weight loss drug Alli after receiving reports of unknown pills and tablets in the bottles.                     

Mylan Wins Breach of Contract Case Against GSK

March 27, 2014 8:50 am | News | Comments

Mylan has announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GSK relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

GSK’s Phase III Cancer Immunotherapeutic Study Misses First Co-Primary Endpoints

March 21, 2014 8:49 am | News | Comments

Agenus Inc. announced that GlaxoSmithKline’s MAGRIT i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon ® adjuvant, did not meet its first or second co-primary endpoint.

HIV Prevention Drug Studies Show Big Promise

March 4, 2014 1:32 pm | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

New research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV.              

Advertisement

Pharma Data Play Larger Role in Olympic Drug Tests

February 10, 2014 8:34 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.     

GlaxoSmithKline Profits Nearly Triple in Fourth Quarter

February 5, 2014 9:06 am | News | Comments

GlaxoSmithKline says fourth-quarter earnings nearly tripled and sales rose 5 percent, even as an ongoing investigation hurt business in China.                  

Partners in New NIH-Industry Project to Find Meds

February 4, 2014 1:43 pm | by The Associated Press | News | Comments

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

Ligand, Glaxo Drug Gets Special FDA Designation

February 3, 2014 3:16 pm | by The Associated Press | News | Comments

Ligand Pharmaceuticals announced that its drug Promacta has received "breakthrough" designation by U.S. regulators for a new use in patients with a rare form of anemia. Ligand and its partner GlaxoSmithKline already market the pill to treat chronic hepatitis C and a rare condition called chronic immune thrombocytopenic purpura, in which the body attacks its own platelets.

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma

January 10, 2014 4:01 pm | News | Comments

The FDA has approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage). In May 2013, the FDA approved both drugs as single agents to treat patients with unresectable or metastatic melanoma.

Advertisement

Santaris Pharma A/S and GSK to Develop RNA-Targeted Medicines

January 10, 2014 8:11 am | News | Comments

Santaris Pharma A/S has signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines.      

FDA Approves New Combination Inhaler Drug

December 18, 2013 1:50 pm | News | Comments

The Food and Drug Administration has approved a new once-a-day inhaler from GlaxoSmithKline PLC that combines two drugs to treat lung disease.                  

Merck and GSK to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

December 18, 2013 7:58 am | News | Comments

Merck has announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

GSK to Change the Way it Promotes Drugs

December 17, 2013 8:31 am | by DANICA KIRKA, Associated Press | News | Comments

GlaxoSmithKline says it will stop offering financial support to doctors and other health-care professionals to promote its products. The change comes months after GSK was hit by an ongoing investigation of alleged bribery by its employees in China and signals a major shift in the way the company operates.

Theravance and Glaxo Say Asthma Study Succeeded

December 6, 2013 11:46 am | News | Comments

The companies said patients who took Breo Ellipta had a bigger improvement in lung function than patients who took the drug Flonase, which contains one of Breo Ellipta's two main components.         

Takeda Names GSK Exec COO

December 2, 2013 8:47 am | News | Comments

Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.

Whooping Cough Shot Cuts Illness, But Maybe Not Its Spread

November 26, 2013 8:08 am | by MIKE STOBBE, AP Medical Writer | News | Comments

A government study offers a new theory on why the whooping cough vaccine doesn't seem to be working as well as expected. The research suggests that while the vaccine may keep people from getting sick, it doesn't prevent them from spreading whooping cough — also known as pertussis — to others.

FDA Overturns Safety Limits on Diabetes Drug

November 25, 2013 4:55 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | Comments

The Food and Drug Administration is lifting severe safety restrictions on the former blockbuster diabetes pill Avandia, citing recent data suggesting that the much-debated medication does not increase the risk of heart attack.   

FDA Approves Quebec-Made Bird Flu Vaccine for Stockpile Use Only

November 25, 2013 8:15 am | by Helen Branswell, The Canadian Press | News | Comments

The U.S. government has for the first time approved an adjuvanted vaccine to protect against H5N1 bird flu. The vaccine was made by Quebec City-based ID Biomedical, a subsidiary of pharmaceutical giant GlaxoSmithKline.     

Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma

November 21, 2013 8:10 am | News | Comments

Pfizer announced today that it has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.

GlaxoSmithKline Drug Fails in Late-Stage Study

November 12, 2013 9:06 am | by The Associated Press | News | Comments

GlaxoSmithKline says a potential heart disease treatment it acquired as part of a key 2012 company takeover fell short in the main measurement of a late-stage study. Darapladib failed to produce a statistically significant reduction in major cardiovascular events like heart attacks, strokes or death when added to a patient's standard of care.

Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GSK

October 8, 2013 8:06 am | News | Comments

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading